European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatic neoplasms - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer.for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 4.2 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 3 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder for solution for injection - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for infusion - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - degarelix acetate 88.2 mg eqv degarelix - injection, powder, for solution - 80 mg - degarelix acetate 88.2 mg eqv degarelix 80 mg